Helping US clients define their absolute requirements, meeting their expectations and making sound adjustments as their projects proceed


The United States is an important market for GlycoSyn. We first opened our dedicated business development and customer service branch in the United States in 2009. Since then, we have worked with a variety of clients from large pharmaceutical firms to biotech startups, research institutes and government entities, and have been described as the “go-to company for drug discovery projects.”

We have delivered compounds and data resulting in successful IND submissions for US clients and been engaged in late-stage development and validation of two recent processes.

What our US clients like about us

  • Exceptional level of expertise and technical resources
  • Reliable technical advice
  • Can be depended on to meet delivery dates and quality targets
  • Builds close, friendly and highly professional business relationships with clients
  • Great reporting and regular updates
  • Flexible project development to meet client needs
  • Easy access to key project on-site staff
  • A great group of people to work with


"GlycoSyn is building a strong reputation in the United States for outstanding technical expertise and a willingness to go the extra mile to make projects succeed. That flexible service has already earned us valuable referrals from existing clients, and we are keen to get involved in more comprehensive small-molecule projects that extend from research, proof of concept, synthesis and manufacture through to Phase II trials. In today’s world, IP is weightless and drug compound manufacture is often small-scale, so geographical location is no longer a barrier to our global development. In fact, you could argue that clients’ precious intellectual property is better protected in our New Zealand-based research laboratories and ICH Q7-equivalent GMP manufacturing facilities.
We are also able to apply our small molecule carbohydrate expertise across a wide range of pharmaceutical research areas from orphan drug development to complex custom glycan arrays, biomarkers and the creation of exacting analytical standards"

Richard Lauricella, GlycoSyn Business Development Manager, USA